Apollomics, Inc. (NASDAQ:APLM) Sees Large Decrease in Short Interest

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 2,900 shares, a drop of 98.3% from the October 31st total of 168,500 shares. Based on an average trading volume of 283,800 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC grew its position in Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,259,117 shares of the company’s stock after purchasing an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned approximately 1.41% of Apollomics worth $179,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 19.13% of the stock is owned by institutional investors and hedge funds.

Apollomics Stock Up 9.1 %

Shares of APLM traded up $0.74 during mid-day trading on Friday, hitting $8.90. 181,869 shares of the company traded hands, compared to its average volume of 92,959. Apollomics has a 1 year low of $7.55 and a 1 year high of $108.00. The stock has a 50-day moving average price of $12.84 and a two-hundred day moving average price of $17.35.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.